Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

26.48 -5.70 (-17.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers NanoVibronix (NASDAQ:NAOV) share... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Erytech Pharma (NASDAQ:ERYP) sha... 
Via Benzinga
Unusual Options Activity Insight: Cassava Sciences
On Friday, shares of Cassava Sciences (NASDAQ:SAVA) saw u... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Erytech Pharma (NASDAQ:ERYP) shares moved upwards by 79.56% to $7.38 during Friday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
A Forgettable Week For Alzheimer's Treatment Stocks
Two of our top names that spiked last week come back down to earth. This is why we hedge. 
Via Talk Markets
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... 
Via Benzinga
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data
As Cassava Sciences made progress in treating Alzheimer's, SAVA stock is on a powerful path to significantly higher prices. 
Via InvestorPlace
70 Biggest Movers From Yesterday
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private... 
Via Benzinga
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business. 
Via The Motley Fool
Understanding Cassava Sciences's Unusual Options Activity
Cassava Sciences (NASDAQ:SAVA) shares experienced unusual options activity on Thursday. The stock price moved down to $107.95 following the option alert. Sentiment: BEARISH... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NanoVibronix (NASDAQ:NAOV) share... 
Via Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration approval for UroShield from TGA Australia.... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates
Following the market opening Thursday, the Dow traded up 0.44% to 35,085.92 while the NASDAQ rose 0.27% to 14,802.51. The S&P also rose, gaining 0.45% to 4,420.49. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Cocrystal Pharma (NASDAQ:COCP) stock moved upwards by 30.9% to $1.44 during Thursday's pre-market session. The company's market cap stands at $140.3... 
Via Benzinga
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease. 
Via The Motley Fool
Cassava Sciences Stock Looks Ready To Break Out If This Pattern Is Confirmed
Cassava Sciences Inc. (NASDAQ: SAVA) shares were moving Monday after the company announced positive clinical data with SavaDx. SavaDx is an investigational diagnostic to... 
Via Benzinga
Don't Get Faked Out By The Fear & Greed Index
False positives can prevent gains. Consider another approach. 
Via Talk Markets
Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer’s Results
Cassava Sciences stock could jump with its upcoming Alzheimer's results. SAVA stock options show the lofty expectations investors have. 
Via InvestorPlace
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Stocks That Hit 52-Week Highs On Monday
This morning 121 companies reached new 52-week highs. Areas of Significance: Alphabet (NASDAQ:GOOGL) was the largest company by market cap to set a new 52-week high... 
Via Benzinga
An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments
Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment. Two Stocks Spike On Alzheimer... 
Via Benzinga
Update On A Bear-Proof Portfolio: The Portfolio We Presented Earlier This Week Is Off To A Fast Start
Japanese gameshow contestant versus bear. Image via TMZ. Bear-Proof Portfolio Update Here's the "bear-proof" portfolio we presented in our pre-market post on... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell. 
Via Investor's Business Daily
An Unforgettable Week For Alzheimer's Treatment Stocks
Two of our recent top stocks spiked on news of potentially promising Alzheimer's treatments this week. They're both risky names, so we look at how to hold them without losing your shirt. 
Via Talk Markets
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis
On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14,... 
Via Benzinga
Update On A Bear-Proof Portfolio
A quick update on the portfolio we presented here in our pre-market post on Tuesday. 
Via Talk Markets
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback